Toggle Main Menu Toggle Search

Open Access padlockePrints

UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO

Lookup NU author(s): Professor Olaf Heidenreich

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

The t(8;21) rearrangement, which creates the AML1-ETO fusion protein, represents the most common chromosomal translocation in acute myeloid leukemia (AML). Clinical data suggest that CBL mutations are a frequent event in t(8;21) AML, but the role of CBL in AML1-ETO-induced leukemia has not been investigated. In this study, we demonstrate that CBL mutations collaborate with AML1-ETO to expand human CD34+ cells both in vitro and in a xenograft model. CBL depletion by shRNA also promotes the growth of AML1-ETO cells, demonstrating the inhibitory function of endogenous CBL in t(8;21) AML. Mechanistically, loss of CBL function confers hyper-responsiveness to thrombopoietin and enhances STAT5/AKT/ERK/Src signaling in AML1-ETO cells. Interestingly, we found the protein tyrosine phosphatase UBASH3B/Sts-1, which is known to inhibit CBL function, is upregulated by AML1-ETO through transcriptional and miR-9-mediated regulation. UBASH3B/Sts-1 depletion induces an aberrant pattern of CBL phosphorylation and impairs proliferation in AML1-ETO cells. The growth inhibition caused by UBASH3B/Sts-1 depletion can be rescued by ectopic expression of CBL mutants, suggesting that UBASH3B/Sts-1 supports the growth of AML1-ETO cells partly through modulation of CBL function. Our study reveals a role of CBL in restricting myeloid proliferation of human AML1-ETO-induced leukemia, and identifies UBASH3B/Sts-1 as a potential target for pharmaceutical intervention.


Publication metadata

Author(s): Goyama S, Schibler J, Gasilina A, Shrestha M, Lin S, Link KA, Chen J, Whitman SP, Bloomfield CD, Nicolet D, Assi SA, Ptasinska A, Heidenreich O, Bonifer C, Kitamura T, Nassar NN, Mulloy JC

Publication type: Article

Publication status: Published

Journal: Leukemia

Year: 2016

Volume: 30

Issue: 3

Pages: 728-739

Print publication date: 01/03/2016

Online publication date: 09/10/2015

Acceptance date: 30/09/2015

ISSN (print): 0887-6924

ISSN (electronic): 1476-5551

Publisher: Nature Publishing Group

URL: http://dx.doi.org/10.1038/leu.2015.275

DOI: 10.1038/leu.2015.275


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
CancerFree Kids Foundation for Cancer Research
Leukemia and Lymphoma Society
Institutional Clinical and Translational Science Award
12007Leukaemia Lymphoma Research
12055Leukaemia Lymphoma Research
1UL1RR026314-01NIH/NCRR
CA101140Coleman Leukemia Research Foundation
CA140158Coleman Leukemia Research Foundation
CA180861Coleman Leukemia Research Foundation
DK090971Center of Excellence in Molecular Hematology P30 award
CA178454JSPS Postdoctoral Fellowship for Research Abroad
MO1 RR 08084Translational Trials Development and Support Laboratory award

Share